MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Coherus Oncology, Inc. (CHRS)

Coherus Oncology, Inc. (CHRS)

|||

Balance Sheets Overview

Current Ratio
177.18%
Quick Ratio
169.67%
Cash Ratio
109.82%
Debt to Asset Ratio
68.18%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Investments in marketable securi...
    • Trade receivables, net
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Term loan, non-current
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
82,923
115,238
88,879
103,352
Investments in marketable securities
22,383
51,810
83,246
88,311
Trade receivables, net
13,881
22,064
17,815
9,245
Tsa receivables, net
372
446
603
241,251
Inventory
5,667
4,825
3,172
2,048
Prepaid manufacturing
3,208
2,273
6,758
8,048
Other prepaids and current assets
5,354
9,379
6,233
8,700
Total current assets
133,788
206,035
206,706
460,955
Property and equipment, net
865
1,094
1,345
1,633
Inventory, non-current
8,425
9,688
-
-
Intangible assets, net
44,989
45,614
46,239
49,484
Other assets, non-current
3,116
3,591
4,053
4,447
Total assets
191,183
266,022
258,343
516,519
Accounts payable
13,168
11,479
9,915
24,893
Accrued rebates, fees and reserves
14,894
28,766
30,397
67,010
Tsa payables and accrued liabilities
22,660
61,605
65,065
253,908
Accrued compensation
9,937
15,280
14,579
13,385
Accrued and other current liabilities
14,851
15,202
20,430
13,101
Total current liabilities
75,510
132,332
140,386
372,297
Term loan, non-current
37,247
37,147
37,051
36,957
Lease liabilities, non-current
-
954
1,457
1,946
Other liabilities, non-current
17,588
16,966
18,435
17,545
Total liabilities
130,345
187,399
197,329
428,745
Common stock (0.0001 par value shares authorized 300,000,000 shares issued and outstanding 154,470,363 and 121,154,925 at june 30, 2026 and december 31, 2025, respectively)
15
15
12
12
Additional paid-in capital
1,503,031
1,500,172
1,444,166
1,433,291
Accumulated other comprehensive loss
-281
-268
-195
-203
Accumulated deficit
-1,441,927
-1,421,296
-1,382,969
-1,345,326
Total stockholders' equity
60,838
78,623
61,014
87,774
Total liabilities and stockholders' equity
191,183
266,022
258,343
516,519
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$82,923K (-61.77%↓ Y/Y)Investments in marketablesecurities$22,383K (7.90%↑ Y/Y)Trade receivables,net$13,881K (171.70%↑ Y/Y)Inventory$5,667K (25.57%↑ Y/Y)Other prepaids andcurrent assets$5,354K (-54.30%↓ Y/Y)Prepaid manufacturing$3,208K (-52.12%↓ Y/Y)Tsa receivables,net$372K (-99.68%↓ Y/Y)Total current assets$133,788K (-64.81%↓ Y/Y)Intangible assets, net$44,989K (-14.00%↓ Y/Y)Inventory, non-current$8,425K Other assets,non-current$3,116K (-38.17%↓ Y/Y)Property and equipment,net$865K (-54.64%↓ Y/Y)Total assets$191,183K (-56.50%↓ Y/Y)Total liabilities andstockholders' equity$191,183K (-56.50%↓ Y/Y)Total liabilities$130,345K (-59.22%↓ Y/Y)Total stockholders'equity$60,838K (-49.23%↓ Y/Y)Accumulated deficit-$1,441,927K (-10.09%↓ Y/Y)Accumulated othercomprehensive loss-$281K (-2.18%↓ Y/Y)Total currentliabilities$75,510K (-71.36%↓ Y/Y)Term loan,non-current$37,247K (1.03%↑ Y/Y)Other liabilities,non-current$17,588K (5.10%↑ Y/Y)Additional paid-in capital$1,503,031K (5.12%↑ Y/Y)Common stock (0.0001par value shares...$15K (25.00%↑ Y/Y)Tsa payables andaccrued liabilities$22,660K (-78.21%↓ Y/Y)Accrued rebates, feesand reserves$14,894K (-84.62%↓ Y/Y)Accrued and othercurrent liabilities$14,851K (4.74%↑ Y/Y)Accounts payable$13,168K (-65.00%↓ Y/Y)Accrued compensation$9,937K (-9.79%↓ Y/Y)